Serosubtypes and PorA Types of Neisseria meningitidis Serogroup B Isolated in Brazil during 1997-1998: Overview and Implications for Vaccine Development
Open Access
- 1 August 2001
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 39 (8) , 2897-2903
- https://doi.org/10.1128/jcm.39.8.2897-2903.2001
Abstract
Meningococcal disease caused by N. meningitidis serogroup B (MenB) has been endemic in Brazil since 1997. In this study, we determined the prevalence of serosubtypes of MenB isolated in 10 Brazilian states and the Federal District during 1997 and 1998 and investigated the extent of PorA VR sequence variation among the most prevalent serosubtypes to evaluate the possible use of an outer membrane vesicle (OMV)-, PorA-based vaccine to prevent meningococcal disease in Brazil. During this period, a total of 8,932 cases of meningococcal disease were reported. Only 42% ( n = 3,751) of the reported cases were laboratory confirmed, and about 60% ( n = 2,255) of those were identified as MenB. Among 1,297 MenB strains selected for this study, the most prevalent serosubtypes were P1.19,15 (66%), P1.7,1 (11%), and P1.7,16 (4%). PorA VR typing showed that 91% of the P1.19,15 strains analyzed had VR1 and VR2 sequences identical to those of the prototype strain. No sequence variation was detected among the 40 strains representing all isolated MenB P1.7,16 strains in the three southern states, where this serosubtype accounts for 75% of the serosubtypes identified. Similarly, all P1.7,1 strains were identified by PorA typing as P1.7-1,1. Although further improvements in the reporting of cases and collection of strains in Brazil are needed, our data suggest that a trivalent OMV-based vaccine prepared with PorA types P1.19,15, P1.7-1,1, and P1.7,16 may be appropriate to control serogroup B meningococcal disease in most of the Brazilian states.Keywords
This publication has 30 references indexed in Scilit:
- Neisseria meningitidis: vaccines and vaccine candidatesJournal of Infection, 1996
- Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccineVaccine, 1996
- Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, ChileVaccine, 1995
- Class 1 outer membrane protein of Neisseria meningitidis: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiologyMolecular Microbiology, 1993
- Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteinsJournal of Medical Microbiology, 1993
- Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISAJournal of Medical Microbiology, 1990
- Definition of meningococcal class 1 OMP subtyping antigens by monoclonal antibodiesFEMS Microbiology Letters, 1988
- An integrated molecular and immunological approach towards a meningococcal group B vaccineVaccine, 1987
- Epidemic Disease due to Serogroup C Neisseria meningitidis in Sao Paulo, BrazilThe Journal of Infectious Diseases, 1974
- Immunologic Response of Man to Group B Meningococcal Polysaccharide VaccinesThe Journal of Infectious Diseases, 1972